NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled
NCT01827267 2018-07-03Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerPuma Biotechnology, Inc.Phase 2 Completed62 enrolled 12 charts